Please assess the completion status of the following clinical trial:

Trial Title: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed adenocarcinoma of the GEJ (type I-III) or the stomach (uT2, uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following specifications:~   * Medical and technical operability~  * Centralized detection of either an adenocarcinoma with HER-2 3+ (IHC) or HER-2 2+ (IHC) with amplification proven by FISH, SISH or CISH~2. No preceding cytotoxic or targeted therapy~3. No prior partial or complete tumor resection~4. Exclusion of the infiltration of any adjacent organs or structures by CT or MRI~5. Exclusion of distant metastasis by CT or MRI of thorax and abdomen, and bone scan (if osseous lesions are suspected due to clinical signs)~6. Female and male patients ≥ 18 years. Patients in reproductive age must be willing to use adequate contraception during the study and for 7 months after the end of pertuzumab and Herceptin treatment (Appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start.~7. ECOG ≤ 2~8. Laparoscopic exclusion of peritoneal carcinomatosis, if suspected clinically~9. Adequate haematological, hepatic and renal function parameters:~   * Leukocytes ≥ 3.000/mm³, platelets ≥ 100.000/mm3~  * Serum creatinine ≤ 1.5 x upper limit of normal, or GFR \> 40 ml/min~  * Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.5 x upper limit of normal, alkaline phosphatase ≤ 6 x upper limit of normal~10. LVEF value \> 55 %, as assessed by echocardiography~11. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures~Exclusion Criteria:~1. Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastasis!)~2. Known hypersensitivity against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel~3. Other known contraindications against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel~4. Documented history of congestive heart failure of any NYHA, myocardial infarction within the past 6 months before the first dose of study treatment~5. Clinically significant valvular defect , history of poorly controlled arterial hypertension (systolic blood pressure \> 180 mmHG or diastolic blood pressure \> 100 mmHg) or uncontrollable high-risk cardiac arrhythmia (i.e tachycardia with a heart rate \> 100/min at rest), significant ventricular arrhythmia (ventricular tachycardia) or higher grade atrioventricular-block (second degree AV-block Type 2 (Mobitz2) or third degree AV-block)~6. Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix~7. Known brain metastases~8. Other severe internal disease or acute infection~9. Peripheral polyneuropathy ≥ NCI Grade II~10. Chronic inflammatory bowel disease~11. Clinically significant active GI bleeding~12. On-treatment participation in another clinical study in the period 30 days prior to inclusion and during the study~13. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.~14. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)~15. Any other concurrent antineoplastic treatment including irradiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- FLOT alone (Type: EXPERIMENTAL): Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
- FLOT + Herceptin/Pertuzumab (Type: EXPERIMENTAL): Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete